HLS Therapeutics Inc experienced a notable decline in stock price this week amid mixed financial results.
HLS Therapeutics Inc (HLS.TO) has seen a downward trend in its stock performance, closing at C$3.60, down 3.73% on the day and 1.10% for the week. The company's recent financial disclosures and product launches have not yet translated into positive market sentiment, reflecting ongoing challenges in the healthcare sector.
Advertisement
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$116.01M
52W high
$5.76
52W low
$3.56
1W change
-1.10%
Beta
0.86
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 103.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.36
+103.8% Upside
Current Price
C$3.61
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
36.0%
Annualized
90-Day Vol
28.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.02
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.40 | C$3.00 – C$3.85 |
| 60 trading days | C$3.20 | C$2.69 – C$3.82 |
| 90 trading days | C$3.02 | C$2.43 – C$3.75 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider HLS Therapeutics' recent financial performance and the implications of its product launches while weighing the stock's potential recovery against its current downward trend.
HLS Therapeutics Reports Q2 2026 Revenue of $14.2 Million
The company reported an Adjusted EBITDA of $5.2 million but continues to face pressures with a profit margin of -15.2%.
Bull case
HLS Therapeutics has launched NILEMDO™ in Canada, a product that addresses a significant unmet need in cardiovascular care. This could lead to future revenue growth as more patients gain access to this treatment option.
Bear case
Despite the recent product launches, HLS has reported negative profit margins and declining stock prices. This indicates potential operational challenges and market skepticism about the company's ability to turn things around.
Weekly Price Action
Advertisement
HLS Therapeutics Inc's stock closed at C$3.60 on Thursday, reflecting a decrease of 3.73% for the day and a slightly smaller decline of 1.10% over the week. This downward trend continues a year-to-date decline of 25.57%, indicating ongoing investor concerns.
Recent Company News
Despite no major news releases this week, HLS Therapeutics has been in the headlines recently for its financial results. The company reported Q2 2026 revenue of $14.2 million, which was an improvement from previous quarters, yet the stock has not reacted positively. HLS also launched NILEMDO™, a new treatment option for cholesterol management, which could potentially enhance its market position.
Technical Picture
From a technical standpoint, HLS Therapeutics is trading below both its 50-day moving average of C$4.09 and its 200-day moving average of C$4.48, indicating a bearish trend. The stock has a beta of 0.86, suggesting it is less volatile than the market. Currently, the stock is near the lower end of its 52-week range of C$3.56 to C$5.76, which could suggest limited downside risk but also reflects investor caution.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
